Skip to product information
1 of 1

Soranni (Sorafenib)

Soranni (Sorafenib)

Model Number: RL1420230901102
Brand Name: Soranni
Origin: Generic drug, LAOS.
Small Orders: Small batches also available
View full details
Packaging Size: 200mg*56Tablets/Box
Strength: 200mg
Composition: Sorafenib
Treatment: kidney cancer (advanced renal cell carcinoma),liver cancer (hepatocellular carcinoma)
Form: Tablet
Brand: Soranni
Quantity Unit: 56Tablets/Box
Manufacturer: Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.(TLPH)
Indications Including: unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and local recovery that is refractory to radioactive iodine therapy Hair or metastasis, and advanced differentiated thyroid cancer. Dose and administration method
  1. Method of administration
  • 400mg (2 tablets) orally, twice a day, on an empty stomach.
  • To deal with suspected adverse drug reactions, treatment may need to be interrupted and/or dose reduced. The dose can be reduced To 400mg once a day or to 400mg, once every other day.
  1. Dosage specifications
  • Tablets, 200mg.
  1. Contraindications
  • People who are known to be allergic to sorafenib or any other components of the drug should not use sorafenib.
  • In patients with squamous cell lung cancer, sorafenib is contraindicated in combination with carboplatin and paclitaxel.
Warnings and Precautions
  • Myocardial ischemia and/or infarction: consider temporarily or permanently discontinuing sorafenib.
  • Bleeding: If bleeding requires medical intervention, consider discontinuing sorafenib.
  • Hypertension: 6 weeks before treatment, regularly monitor blood pressure every week. Follow-up treatment should also be monitored regularly.
  • Skin toxicity: Interrupt and/or reduce the dose. Severe or persistent skin toxicity, or pregnant Stop taking the medication when you suspect Stevens-John syndrome and toxic epidermal necrolysis.
  • Gastrointestinal perforation: stop taking sorafenib.
  • Prolonged QT interval: Patients with high risk of ventricular arrhythmia regularly monitor ECG and electrolyte levels.
  • Drug-induced hepatotoxicity: monitor liver function regularly; stop if there is an unexplained rise in transaminase Stop taking medicine.
  • Embryo toxicity: It is recommended that women of childbearing age avoid pregnancy when taking the drug.
  • Thyroid-stimulating hormone (TSH) damage in differentiated thyroid cancer (DTC): monitor TSH once a month,
(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)
  • Thyroid replacement therapy is suitable for patients with thyroid cancer.
Adverse reactions The most common adverse reactions related to sorafenib (≥20%): diarrhea, fatigue, infection, baldness, Hand and foot skin reactions, rash, weight loss, anorexia, nausea, gastrointestinal pain and abdominal pain, high blood pressure and blood. storage method Shading, cool and dry place

Everyone Deserves Access to Life-saving Treatment Of Cancer. We are a Trusted Cancer Medicine seller delivering certified medications to every corner of the world.